❉ Buffybot wonderful businesses, fair prices

← back

ABBV AbbVie

pharma · 2026-10-12

N/A
too hard · 61
Owner-earnings value$118.73
Price$276.47
Margin of safety -57.1%

Quality gate · 61/100

Returns on capital 7.3/30
Consistency 18.8/22
Margins / pricing power 15.8/16
Balance sheet 4.6/16
Cash conversion 10/10
Capital allocation 4.5/6

⚠ negative book equity · sub-hurdle returns (median roic 9% < 9%)

Median ROIC8.8%
Gross margin71.5%
Net debt / EBITDA3.2x
FCF conversion325%
Share count / yr-0.0%
Profitable years4/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)12.88B
Owner-earnings yield2.6%
Free-cash-flow yield3.7%
Growth used (normalized)1.8%
Market-implied growth (reverse DCF)22.6%
Terminal growth3.0%
Discount rate (hurdle)9.0%

Projected owner earnings

YrOwner earningsGrowthPV
113.11B 1.8%12.03B
213.36B 1.9%11.24B
313.63B 2.0%10.52B
413.92B 2.2%9.86B
514.24B 2.3%9.26B
614.59B 2.4%8.70B
714.97B 2.6%8.19B
815.38B 2.7%7.72B
915.82B 2.9%7.28B
1016.29B 3.0%6.88B

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~23%/yr owner-earnings growth over 10y (reverse DCF); model credits 2%.

History

DateQualityPriceValueMoSRating
2026-10-12 61 $276.47 $118.73 -57.1% N/A
2026-09-08 61 $256.46 $118.73 -53.7% N/A
2026-08-06 58 $246.20 $96.10 -61.0% N/A
2026-07-06 58 $261.07 $96.12 -63.2% N/A
2026-07-02 58 $251.06 $96.12 -61.7% N/A
2026-06-29 58 $253.35 $96.12 -62.1% N/A
2026-06-25 58 $234.89 $96.12 -59.1% N/A
2026-06-23 58 $234.76 $96.12 -59.1% N/A